Refine
Year of publication
- 2019 (254) (remove)
Document Type
- Conference Proceeding (101)
- Article (92)
- Bachelor Thesis (22)
- Book (15)
- Doctoral Thesis (7)
- Report (6)
- Part of a Book (4)
- Master's Thesis (4)
- Patent (2)
- Other (1)
Language
- German (127)
- English (123)
- Multiple languages (4)
Keywords
- Abschlussarbeit (6)
- Bachelorarbeit A/H (3)
- Additive Manufacturing (2)
- Aktorik (2)
- EMG (2)
- Electrophoresis, Capillary/instrumentation/methods (2)
- Exoskelett (2)
- Exosuit (2)
- Humans (2)
- muskelgesteuert (2)
Institute
- Wirtschaftswissenschaften (94)
- Maschinenbau und Werkstofftechnik (67)
- Optik und Mechatronik (46)
- Elektronik und Informatik (22)
- Chemie (15)
It has been recently shown, that certain strains/isolates of Bacillus subtilis can be used as a probiotic for humans. The production of the macrocyclic sactibiotic subtilosin in B. subtilis ATCC 6633 is highly regulated. To improve the subtilosin productivity of B. subtilis, different growth conditions were compared for maximal expression of the sbo promoter that regulates the expression of the subtilosin biosynthetic gene cluster. Oxygen-limiting conditions led to a strong increase of sbo promoter activities compared to aerobic conditions, and accordingly, the subtilosin amount determined by reversed phase HPLC (7.8 mg/L) was 15-fold superior to the amount of aerobic grown cultures (0.5 mg/L). A further promising enhancement of the subtilosin yield was achieved using a deletion mutant that is avoiding the general transition state regulator protein AbrB. The subtilosin titer of 42 mg/L produced by ΔabrB cells grown under oxygen-limiting conditions corresponds to an 84-fold increase compared to the subtilosin titer obtained from B. subtilis wild type cells propagated in aerobic conditions. Furthermore, evidence is provided that oxygen-limiting conditions led to a strong decrease in the productivity of the lantipeptide subtilin suggesting contrary regulatory mechanisms for the B. subtilis antimicrobials subtilin and subtilosin.
Drugs containing amine groups react with CO2 to form crystalline ammonium carbamates or carbamic acids. In this approach, both the cation and anion of the salt, or the neutral CO2 adduct, are derived from the parent drug, generating new crystalline versions in a 'masked' or prodrug form. It is proposed that this approach may serve as a valuable new tool in engineering the physical properties of drugs for formulation purposes.
Virtuous cycles
(2019)